With a career that encompasses legal experience in both Munich and New York, Dr Tim Reinhard combines skills as a commercial mediator with expertise in biotechnology and medtech.
Today, Tim heads up Osborne Clarke’s German life sciences and healthcare group, advising national and international pharmaceutical, biotech and medtech companies clients in IP-related issues and regulatory matters.
He also provides legal guidance in the process of product development, including the negotiation of clinical trial, licensing and R&D agreements. And while technology plays an ever-growing role in the sector, Tim advises his clients in all legal aspects connected with the provision of digital healthcare offerings, such as digital applications, telemedicine and online pharmacies.
Alongside his advisory services, he represents his life sciences clients in litigation, primarily in patent infringement and competition law proceedings, also focusing on employee invention law.
As a trained commercial mediator, Tim supports his clients in mediation proceedings and is regularly called upon as a commercial mediator in IP-related disputes in the life sciences and healthcare sector.
He studied in Würzburg and obtained a doctorate in the area of intellectual property law before qualifying as a lawyer in 1996. Prior to joining Osborne Clarke in 2005, Tim held roles with an international law firm in Munich and New York.
Sylphar NV and KaroPharma AB
Osborne Clarke advises Sylphar NV and Karo Pharma AB on purchase of Satin Naturel, read more
Osborne Clarke advises OSF Digital on the acquisition of netnomics, read more
Galileo Global Education Germany
Osborne Clarke advises Galileo on acquisition of AKAD University, read more
Keen Venture Partners
Osborne Clarke advises Keen Venture Partners on EUR 25 million investment in Lendis, read more
Osborne Clarke advises Highland Europe on investment in SoSafe, read more
Osborne Clarke has advised DoorDash on USD 750 million Series B financing round of rapid delivery firm Flink SE, read more
Osborne Clarke advises MA Ventures on investment in Lykon, read more
Osborne Clarke advises Signiant on acquisition of Lesspain Software, read more
Providence Strategic Growth
Osborne Clarke advises Providence Strategic Growth on investment in Hornetsecurity, read more
Osborne Clarke named "Law Firm of the Year Germany 2020", read more
Osborne Clarke advises Cathay Innovation on MEDWING’s 28 million financing round, read more
Osborne Clarke advises Redalpine on EUR 6 million financing round in lengoo, read more
Osborne Clarke advises CeleraOne on sale to Axel Springer, read more
Osborne Clarke advises Earlybird on €4m investment in Bitwala, read more
Osborne Clarke advised Goodix Technology on acquisition of Commsolid, read more
Advised TomTec on its takeover by Philips, read more
Automotive software client
Helped a client expand their presence in the automotive software markets by navigating them through corporate transactions in Italy, Germany, Spain and the United Kingdom
Advised this US medical device company on its entry to the German/European market by developing terms and conditions, purchase and rebate agreements with clinics, patient information brochures and patient consent forms
Uptake Medical Inc.
Advised this US medical device company that has developed a device for treating emphysema on its entry into the German market
Vakzine Projektmanagement GmbH
Advised in a number of international drug development agreements and regulatory matters
Advised Allgeier on acquisition of Ciber Germany, read more
Could international and European legal obstacles jeopardise the German government's legislative plan to legalise cannabis?
Royalty Pharma: the CJEU's latest decision on Supplementary Protection Certificates addresses when medicinal products can be "protected by a basic...
With less than four months until the UK officially leaves the EU, amid confidence votes and delayed votes in the...